Acura Pharmaceuticals Inc. (NASDAQ:ACUR)

CAPS Rating: 2 out of 5

A pharmaceutical company engaged in research, development and manufacture of innovative Aversion(r) Technology and related product candidates.

Results 1 - 16 of 16

Recs

0
Member Avatar asilverp (72.57) Submitted: 8/28/2014 12:01:19 PM : Underperform Start Price: $0.96 ACUR Score: +49.75

high p/s, bad relative strength = high probability of it ending up in the trashbin

Recs

0
Member Avatar jewing7 (< 20) Submitted: 2/26/2014 11:06:24 AM : Outperform Start Price: $1.90 ACUR Score: -84.73

A little over one month ago I added Acura to my portfolio because it was pretty cheap, and the Total Yield of the company was about 15%. So far this company has done nothing but skyrocket my portfolio from a 2% total increase, to a 7% increase in only 5 weeks, and shooting me toward an early retirement. I will definitely be buying more of this stock soon.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 1/30/2014 3:33:35 AM : Outperform Start Price: $1.71 ACUR Score: -85.75

DRug delivery best sector 2014 January

Recs

0
Member Avatar naughtyguy (33.00) Submitted: 8/4/2013 11:36:19 PM : Outperform Start Price: $2.63 ACUR Score: -111.87

Obviously I green thumbed too early. If it gets another 20 cents cheaper, I think I'll be a real buyer. (It is about $1.85 at the time of this writing).

Recs

0
Member Avatar whoodatstockhot (81.62) Submitted: 7/1/2013 5:38:33 PM : Outperform Start Price: $2.23 ACUR Score: -105.64

ACUR is poiised to takeover the multibillion-dollar market for abuse resistant drugs, a mulitibillion dollar market, as it pulls generic drugs off the market. It has an extensive pipline of technologies, 25 million in cash in assets, no debt, an FDA tailwind at their back, and a nice partnership with PFE. Nice little spec here, and I expect significant gains as investors start to notice the exceptional growth available to ACUR. Nexafed also provides an outlet for some major revenue potential going forward. ACUR should move into the $4 dollar range in coming months and much higher longer term if it continues to execute. Buyout potential also extremely high.

Recs

0
Member Avatar CharDAt (< 20) Submitted: 6/27/2013 8:37:39 PM : Outperform Start Price: $1.92 ACUR Score: -102.26

ACUR have a proven (bio) technology that allows effective medications with massive markets to be sold (again).

Recs

0
Member Avatar RXDOC73 (99.37) Submitted: 7/31/2012 8:11:42 AM : Outperform Start Price: $2.00 ACUR Score: -124.03

Buy out target at this low price!

Recs

0
Member Avatar maniacdog (< 20) Submitted: 3/2/2012 8:30:51 AM : Outperform Start Price: $3.17 ACUR Score: -134.46

It does not matter whether their oxycodone drug Onexa cuts abuse or not doctors are under such pressure when they prescribe oxy they will prescribe this new pill just to keep in the good graces of the DEA. Of course this drug will not curb abuse always a way around it, but if somebody wants pain meds Onexa will become the norm whether it works or not.

Recs

0
Member Avatar Lcrazylegs84 (< 20) Submitted: 10/1/2011 1:06:09 AM : Outperform Start Price: $3.50 ACUR Score: -169.84

going up

Recs

0
Member Avatar thebigpicture37 (< 20) Submitted: 6/22/2011 11:47:13 AM : Outperform Start Price: $3.97 ACUR Score: -147.30

The 20 million royalty will be paid to Acura Pharma in late June or early July. Also Pfizer plans to partner with Acura on other opioid drugs using the Aversion TM technology. However my favorite is an OTC product with pseudoephedrine which will be rolled out later this year. Nexafed TM using Impede TM technology. This drug will have the same ingredients as Sudafed TM and brand name.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 6/20/2011 10:53:32 AM : Outperform Start Price: $4.98 ACUR Score: -152.62

fda approval

Recs

0
Member Avatar pyupie0216 (< 20) Submitted: 8/18/2010 5:55:20 PM : Underperform Start Price: $2.44 ACUR Score: +171.00

screen

Recs

0
Member Avatar steelersnextat7 (< 20) Submitted: 9/22/2009 2:10:56 AM : Outperform Start Price: $4.88 ACUR Score: -183.38

FDA approval is looming in Jan to March 2010 when it does acura will hit 12 to 15 or be bought or both king will scoop it up

Recs

0
Member Avatar manvsmonkey (79.14) Submitted: 7/28/2008 2:09:10 PM : Outperform Start Price: $7.30 ACUR Score: -165.47

seems like the phase III trial is going well

http://seekingalpha.com/article/87373-a-biotech-bloom-in-july?source=side_bar_long_ideas

Recs

1
Member Avatar davidr825 (< 20) Submitted: 6/13/2008 7:58:39 PM : Outperform Start Price: $9.54 ACUR Score: -152.62

Unique delivery of controlled substances will make this a winner - especially when coupled with King Pharmaceutical

Recs

5
Member Avatar tcampbellla (81.06) Submitted: 10/29/2007 3:16:36 PM : Underperform Start Price: $19.30 ACUR Score: +138.51

No thanks.

Results 1 - 16 of 16

Featured Broker Partners


Advertisement